论文部分内容阅读
最近,在德意志联邦共和国的巴伐利亚州,就用单克隆抗体(McAb)作免疫学治疗的可能性召开了专题讨论会。目前,在人体内应用McAb的许多尝试虽然尚未肯定其优越性,但体外和动物实验所取得的阳性结果足以鼓励人们作进一步的努力。McAb作为治疗试剂的应用仍处于早期阶段,故不能期望立即得到显著的效果。专题讨论会首先讨论了抗体分子的工程学问题。几个实验室提出了不同的策略:应用化学方法将小鼠抗体的Fab与人抗体的Fc偶联成单价抗体;或通过基因工程技术产生
Recently, in Bavaria, Federal Republic of Germany, a symposium was held on the possibility of immunotherapy with monoclonal antibodies (McAbs). At present, many attempts to use McAb in humans have not yet confirmed their superiority, but positive results from in vitro and animal experiments are enough to encourage further efforts. The use of McAb as a therapeutic agent is still in its early stages and therefore no immediate effect can be expected. The symposium first discussed the engineering of antibody molecules. Several laboratories have proposed different strategies: chemically coupling the Fab of a mouse antibody to the Fc of a human antibody into a monovalent antibody; or by genetic engineering techniques